Search

Search Results
Results 4041 - 4050 of 5284 for Active site
  • Drug - 26 Sep 2025
    Consumer Medicine Information (CMI) about Skyrizi intended for persons living in Australia.
  • Drug - 25 Sep 2025
    Consumer Medicine Information (CMI) about Adriamycin intended for persons living in Australia.
  • Drug - 23 Sep 2025
    Consumer Medicine Information (CMI) about Epkinly intended for persons living in Australia.
  • News - 18 Sep 2025
    In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers...
  • Drug - 4 Sep 2025
    Consumer Medicine Information (CMI) about DBL Desferrioxamine Mesylate intended for persons living in Australia.
  • News - 21 Aug 2025
    A new survey of 312 neuroscientists reveals strong support for synaptic connectivity as the basis of long-term memory, but deep divides remain over memory extraction and brain emulation feasibility....
  • Drug - 21 Aug 2025
    Consumer Medicine Information (CMI) about Benlysta intended for persons living in Australia.
  • Drug - 12 Aug 2025
    Consumer Medicine Information (CMI) about Blincyto intended for persons living in Australia.
  • Drug - 8 Aug 2025
    Consumer Medicine Information (CMI) about Abilify Asimtufii intended for persons living in Australia.
  • Drug - 8 Aug 2025
    Consumer Medicine Information (CMI) about Navelbine IV intended for persons living in Australia.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.